CÁNCER DE MAMA LUMINAL
TIPO
ENSAYO
FASE
ESTADO
ADYUVANCIA
CAMBRIA-2: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer
Fase 3
ABIERTO
ELEGANT: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Fase 3
ABIERTO
METASTÁSICO
FOURLIGHT-3: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Fase 3
ABIERTO
INAVO 123: A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Fase 3
ABIERTO
SABINA: PIK3CA/PTEN altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (SABINA)
Metaplásicos
Fase 2
ABIERTO
WIN B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
Fase 1
ABIERTO
PIKTURE 1: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Fase 1
ABIERTO
BT8009-201: Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Fase 2
ABIERTO
ELAINE 3: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Fase 3
ABIERTO
DESTINY-Breast 15: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Fase 3
ABIERTO
ADELA: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i
Fase 3
ABIERTO
ELEVATE: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Fase 1 B-2
ABIERTO
MK2870-010: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Fase 3
ABIERTO
DYNASTY-Breast 02: A Study of DB-1303/BNT323 vs Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer
Fase 3
ABIERTO
PONTIAC: Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Fase 2
ABIERTO
BREAKER101:Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Fase 1
ABIERTO
GO46021: A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Fase 1 B-2
ABIERTO
CÁNCER DE MAMA TRIPLE NEGATIVO
TIPO
ENSAYO
FASE
ESTADO
NEOADYUVANCIA
TELESCOPE: Neoadjuvant phase 2 study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer
Fase 2
ABIERTO
MK2870-032: A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Fase 2
ABIERTO
ADYUVANCIA
ASCENT-05: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Fase 3
ABIERTO
MK2870-012:Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Fase 3
ABIERTO
METASTÁSICO
TROPION-Breast 05: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Fase 3
ABIERTO
MK2870-011: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Fase 3
ABIERTO
SABINA: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (SABINA)
Fase 2
ABIERTO
WIN B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
Fase 1
ABIERTO
BT8009-201: Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Fase 2
ABIERTO
BL-B01D1 LUNG-101: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Fase 1
ABIERTO
IZABRIGHT-BREAST01: A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Fase 3
ABIERTO
BNT326-01: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Fase 1
ABIERTO
DIAMOND: Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Fase 2
ABIERTO
CÁNCER DE HER 2 POSITIVO
TIPO
ENSAYO
FASE
ESTADO
METASTÁSICO
DEMETHER: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
Fase 2
ABIERTO
EMPOWHER: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician’s Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Fase 3
ABIERTO
C5731006: A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Fase 1 B-2
ABIERTO
TUXEDO-4: A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Fase 2
ABIERTO
BREAKER101: Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Fase 1
ABIERTO
CÁNCER DE PULMÓN
TIPO
ENSAYO
FASE
ESTADO
METASTÁSICO
REPOSE: REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain metastasis (REPOSE)
Fase 2
ABIERTO
BL-B01D1 LUNG-101: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Fase 1
ABIERTO
HEMATOLOGÍA
TIPO
ENSAYO
FASE
ESTADO
EXS73565: Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Fase 1
ABIERTO